Chiesi Farmaceutici S.p.A. to Acquire Amryt

 Transaction expands Chiesi’s rare disease medicine portfolio

- All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved

- Total Transaction value of up to US$1.48 Billion with upfront consideration representing a 107% premium to Amryt ADS’ closing price on January 6, 2023

- Transaction unanimously approved and recommended by the Boards of both Chiesi and Amryt

https://finance.yahoo.com/news/chiesi-farmaceutici-p-acquire-amryt-200000567.html